There are 2789 resources available
323P - Clinical profile and prognosis of metastatic breast cancer with pseudocirrhosis: A rare and dismal condition
Presenter: Maria Fernanda Simões
Session: ePoster Display
325P - Trends of primary tumor resection in de novo metastatic breast cancer: The experience of a Mexican center
Presenter: Fabio Gonzalez-Mondellini
Session: ePoster Display
326P - National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study
Presenter: Marie Ange Mouret Reynier
Session: ePoster Display
327P - Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole
Presenter: Roya Behrouzi
Session: ePoster Display
328TiP - Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Presenter: Sara Tolaney
Session: ePoster Display
330TiP - Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
Presenter: Marta Vaz Batista
Session: ePoster Display
331TiP - HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Presenter: Lisa Carey
Session: ePoster Display
272P - Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Presenter: Miguel Martin
Session: ePoster Display